A Phase 4 interventional study of Exparel + Bupivacaine and Bupivacaine in C-Section and Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 12 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-06.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary objective: The primary objective of this study is to compare total opioid consumption through 72 hours following EXPAREL+bupivacaine HCl infiltration into the transversus abdominis plane (TAP) after spinal anesthesia to active bupivacaine HCl TAP infiltration after spinal anesthesia in subjects undergoing an elective cesarean section (C-section).
Secondary objective: The secondary objectives are to assess efficacy and safety parameters and patient satisfaction.
This is a Phase-4, multicenter, randomized, double-blind, active-controlled study planned in approximately 152 adult subjects undergoing elective C-section. All subjects will remain in the hospital for up to 72 hours postsurgery.
Screening:
Subjects will be screened within 30 days prior to surgery; screening on the day of surgery will be allowed but is discouraged. During the screening visit, subjects will be assessed for any past or present medical conditions that in the opinion of the investigator would preclude them from study participation. After the informed consent form (ICF) is signed, a medical history, surgical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, alcohol breath test and urine drug screen, and clinical laboratory tests (hematology and chemistry) will be performed.
Day of Surgery:
Pre-operative medications: Use of pre-operative analgesics (eg, opioid medications, acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs]) is prohibited.
Eligible subjects will be randomized in a blinded 1:1 ratio to either:
Intraoperative medications: The intraoperative use of the following medications is discouraged, but may be permitted if clinically indicated based on the investigator's discretion (all medications must be appropriately recorded [ie, drug, dose, and route of administration]): ketamine and midazolam (Versed®). Prophylactic use of dexamethasone for prevention of nausea and vomiting is prohibited.
After delivery of the baby and prior to the TAP infiltration, a small amount of lidocaine (\<2 mL) may be administered subcutaneously to form a skin wheal over the area of the needle insertion site. A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section. A confirmatory ultrasound picture or video will be taken of each side of the abdomen after the TAP needle position has been established and following infiltration of study drug.
TAP infiltration: Subjects randomized to the EXPAREL+bupivacaine group (Group 1) will receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL, administered as 30 mL (10 mL EXPAREL, 10 mL 0.25% bupivacaine HCl, and 10 mL saline) on each side of the abdomen. Subjects randomized to the active bupivacaine group (Group 2) will receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL, administered as 30 mL (10 mL 0.25% bupivacaine HCl and 20 mL saline) on each side of the abdomen.
Postsurgical Analgesia: Patient-controlled analgesia is not permitted. The following multimodal pain regimen will be initiated immediately following the delivery of the baby:
The date, time, and dose of all standardized multimodal pain medications administered must be recorded. Note: The scheduled PO medication will be administered on a q6h schedule only through hospital discharge.
Rescue Medication: Subjects should only receive opioid rescue pain medication upon request for breakthrough pain. Postsurgical rescue medication will comprise PO immediate-release oxycodone (initiated at 5-10 mg every 4 hours [q4h] or as needed [PRN]). If a subject is unable to tolerate PO medication or fails the PO oxycodone rescue, IV morphine (initiated at 1-2 mg) or hydromorphone (initiated at 0.3-0.5 mg) may be administered q4h or PRN. All surgical and postsurgical opioid and other analgesics (pain medications) administered must be documented through Day 14 postsurgery. Additionally, an unscheduled pain intensity score using a 10-cm visual analog scale (VAS) must be completed immediately prior to any rescue medication while in the hospital.
Permitted medications for the prevention and treatment of possible medication side effects include the following and may be used at the discretion of the study site principal investigator:
Postsurgical Assessments:
Subjects will remain in the hospital for up to 72 hours postsurgery. Postsurgical assessments will include:
While in the hospital, subjects will be provided with a Patient Diary and will use the diary to record all scheduled and unscheduled VAS scores. For all scheduled assessments and unscheduled assessments in the hospital, subjects will assess, "How much pain are you experiencing right now" and a vertical mark will be placed on the VAS line to indicate the level of pain experienced at the time of assessment. If a subject is discharged prior to a scheduled VAS assessment, a member of the study site staff will contact the subject to remind her to complete the scheduled VAS assessment at the scheduled time and to record the assessment in the Patient Diary.
At hospital discharge, the subject will be instructed to record in the Patient Diary VAS pain intensity score daily and all pain medications taken following hospital discharge through Day 14.
At home, the subject will assess pain intensity at rest each day at noon (± 4 hours). This assessment should capture her average pain at rest in the prior 24 hours by assessing "What has been your average pain since your last pain assessment?" (ie, from noon on the previous day to the current assessment). At the same time, the subject should record any pain medication (medication name, date, time, and dose) taken in the prior 24 hours.
A phone call will be made to each subject on Day 14 for safety purposes and to inquire as to whether the subject has made any unscheduled phone calls or office visits related to pain; experienced any hospital readmission; or experienced an emergency room visit since hospital discharge. Adverse events (AEs) and serious adverse events (SAEs) will be recorded from the time the ICF is signed through Day 14.
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
Drug: Exparel + Bupivacaine
Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
Drug: Bupivacaine
Drug page: Liposomal Bupivacaine
EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section
The primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.
Time frame: 0-72 hours
Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours
AUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= "no pain" to 30 cm="pain as bad as it could be"). Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, "How much pain are you experiencing right now?" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment. Note higher AUC means more pain over time.
Time frame: 0-72 hours
Opioid Spared Subjects Through 72 Hours
Subjects were considered opioid-spared if: * For 0-72 hours opioid consumption, all doses add up to ≤15mg (oral morphine equivalent dose \[OMED\]) * AND the overall benefit of anesthesia score (OBAS) score was 0 for questions 2, 3, 4, 5, and 6. For the OBAS questionnaire, 0 is considered minimal pain and 4 is considered maximum imaginable pain.
Time frame: 0-72 hours
Total Postsurgical Opioid Consumption Through 24 Hours
Time frame: 0-24 hours
Total Postsurgical Opioid Consumption Through 48 Hours
Time frame: 0-48 hours
Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)
Time frame: 0-168 hours
Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)
Time frame: 0-336 hours
Time to First Rescue Medication Use
The time to a subject's first use of an opioid medication for breakthrough pain after the end of surgery
Time frame: From the end of surgery
Opioid-Free Subjects Through 72 Hours
Percentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hours
Time frame: 0-72 hours
| Milestone | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Started | 96 | 90 |
| Completed | 91 | 83 |
| Not completed | 5 | 7 |
| Withdrew: Lost to follow-up | 5 | 7 |
The primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.
| MED, mg | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section | 15.5 ± 6.67 | 32.0 ± 6.25 |
AUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= "no pain" to 30 cm="pain as bad as it could be"). Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, "How much pain are you experiencing right now?" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment. Note higher AUC means more pain over time.
| cm*hr | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours | 147.9 ± 21.13 | 178.5 ± 19.78 |
Subjects were considered opioid-spared if: * For 0-72 hours opioid consumption, all doses add up to ≤15mg (oral morphine equivalent dose \[OMED\]) * AND the overall benefit of anesthesia score (OBAS) score was 0 for questions 2, 3, 4, 5, and 6. For the OBAS questionnaire, 0 is considered minimal pain and 4 is considered maximum imaginable pain.
| percent of participants | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Opioid Spared Subjects Through 72 Hours | 53.5 | 24.7 |
| MED mg | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Total Postsurgical Opioid Consumption Through 24 Hours | 2.4 ± 1.82 | 5.6 ± 1.70 |
| MED mg | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Total Postsurgical Opioid Consumption Through 48 Hours | 9.1 ± 4.46 | 20.5 ± 4.18 |
| MED mg | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Total Postsurgical Opioid Consumption Through 168 Hours (Day 7) | 23.3 ± 9.75 | 45.8 ± 9.13 |
| MED mg | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Total Postsurgical Opioid Consumption Through 336 Hours (Day 14) | 28.2 ± 11.20 | 47.8 ± 10.49 |
The time to a subject's first use of an opioid medication for breakthrough pain after the end of surgery
| hours | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Time to First Rescue Medication Use | 53.2 (2.3 to 345.2) | 41.1 (2.5 to 345.7) |
Percentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hours
| percent of opioid-free participants | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine |
|---|---|---|
| Opioid-Free Subjects Through 72 Hours | 51.9 | 48.6 |
Collected over Screening through postsurgical Day 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL+Bupivacaine TAP Infiltration | 0/97 (0%) | 3/97 (3.1%) | 63/97 (64.9%) |
| Active Bupivacaine TAP Infiltration | 0/89 (0%) | 3/89 (3.4%) | 50/89 (56.2%) |
| Event | EXPAREL+Bupivacaine TAP Infiltration | Active Bupivacaine TAP Infiltration |
|---|---|---|
| Retained placenta or membranesPregnancy, puerperium and perinatal conditions | 0/97 | 1/89 |
| Gestational hypertensionPregnancy, puerperium and perinatal conditions | 0/97 | 1/89 |
| Postpartum hemorrhagePregnancy, puerperium and perinatal conditions | 0/97 | 1/89 |
| Urinary tract infectionRenal and urinary disorders | 0/97 | 1/89 |
| CardiomyopathyCardiac disorders | 1/97 | 0/89 |
| Abdominal wall hematomaGastrointestinal disorders | 1/97 | 0/89 |
| Panic attackPsychiatric disorders | 1/97 | 0/89 |
| Event | EXPAREL+Bupivacaine TAP Infiltration | Active Bupivacaine TAP Infiltration |
|---|---|---|
| pruritisSkin and subcutaneous tissue disorders | 27/97 | 28/89 |
| NauseaGastrointestinal disorders | 24/97 | 11/89 |
| VomitingGastrointestinal disorders | 12/97 | 6/89 |
| HeadacheNervous system disorders | 6/97 | 10/89 |
| ConstipationGastrointestinal disorders | 6/97 | 4/89 |
| DizzinessNervous system disorders | 6/97 | 5/89 |
| Back painMusculoskeletal and connective tissue disorders | 3/97 | 5/89 |
| RashSkin and subcutaneous tissue disorders | 5/97 | 3/89 |
The safety analysis set includes all subjects who receive study drug. All analyses based on the safety set are by actual treatment received.
| Age, Continuous(years) | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine | Total |
|---|---|---|---|
| Mean | 33.6 ± 5.37 | 33.1 ± 4.43 | 33.4 ± 4.94 |
| Sex: Female, Male(Participants) | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine | Total |
|---|---|---|---|
| Female | 97 | 89 | 186 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 11 | 23 |
| Not Hispanic or Latino | 84 | 78 | 162 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 5 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 15 | 28 |
| White | 67 | 64 | 131 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 11 | 2 | 13 |
| Region of Enrollment(participants) | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine | Total |
|---|---|---|---|
| United States | 97 | 89 | 186 |
| American Society of Anesthesiologists classification(Participants) | EXPAREL 266mg + Immediate Release (IR) Bupivacaine | IR Bupivacaine | Total |
|---|---|---|---|
| ASA 1 | 1 | 1 | 2 |
| ASA 2 | 90 | 80 | 170 |
| ASA 3 | 6 | 8 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Nov 2018, 17 months.
Results were first posted in Jan 2021, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine
Agnosia